1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs

 
• By Mandy Jackson

ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.
ReCode's LNP platform can deliver RNA therapeutics and other genetic medicines • Source: Shutterstock

ReCode Therapeutics and TranscripTx have combined their development of RNA-based medicines under one banner, emerging under the ReCode banner with $80m in series A venture capital to complete preclinical studies and begin clinical trials for two therapeutics candidates designed to treat genetic respiratory diseases. ReCode Therapeutics also will use its new funding to advance its lipid nanoparticle (LNP) platform for organ-specific delivery of RNA therapies and other genetic medicines.

David Lockhart, who was the president and CEO of TranscripTx, is leading the combined company going forward. The ReCode president and CEO said the company has 15 employees between its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.